Endogenex
PrivateLast Round
Series C
Extension
Mar 25, 2026
Total Funding Raised
$240.51M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Endogenex is a medical technology company that develops minimally invasive, endoscopic procedures using non-thermal pulsed electric fields to treat type 2 diabetes by resetting metabolic signaling in the duodenum.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endogenex Comparables
Compare Endogenex with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fractyl Health | 88% | |
| Aqua Medical | 85% | |
| Digma Medical | 85% |
Endogenex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Mar 25, 2026 | ||||
| Series C | Jun 25, 2024 | ||||
| Series B Extension | Oct 11, 2023 | ||||
| Series A | Feb 21, 2023 | ||||
| Series A Extension | Apr 19, 2021 | ||||
Series A | Nov 30, 2018 |
Endogenex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C Extension, Series A Extension, Series C, Series A |
| Arboretum Ventures | Series C Extension, Series C |
| Hatteras Venture Partners | Series C Extension, Series C |
| Orlando Health Ventures | Series C Extension, Series C |
| Santé Ventures | Series C Extension, Series C |
| Intuitive Ventures | Series C Extension, Series A, Series A Extension, Series C |
| Mayo Clinic Ventures | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 36% MoM, reaching 3.4K.
- Mar 25, 2026
$50M Series C Extension round completed.
Endogenex Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Endogenex's valuation, stock price, and market status.
Is Endogenex a public or private company?
Endogenex is a private company.
What is the current stock price of Endogenex?
Endogenex is a private company with no public stock price. No recent secondary market data is available.
How much is Endogenex worth (valuation)?
Valuation information for Endogenex is not publicly available.
Can I buy Endogenex stock?
Endogenex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Endogenex's last funding round?
Endogenex's most recent funding round was Series C Extension on March 25, 2026.
Who are the main investors in Endogenex?
Key investors in Endogenex include Longitude Capital, Arboretum Ventures, Food and Drug Administration, Santé Ventures.
Will Endogenex IPO soon?
No public IPO plans have been announced for Endogenex.
How can I track Endogenex secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Endogenex's secondary market activity and sign up for updates.